BioFluidica
BioFluidica is a privately held biotechnology company that has developed the LiquidScan microfluidics-based liquid biopsy platform, which isolates and enriches rare cells and exosomes from bodily fluids for oncology and prenatal diagnostics researchers.
- Company typePrivate
- Founded2013
- HeadquartersLawrence, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What BioFluidica does
BioFluidica is a privately held biotechnology company that has developed the LiquidScan® platform, a microfluidics-based liquid biopsy system that isolates and enriches rare cells — including circulating tumor cells (CTCs) and fetal trophoblasts — and exosomes/extracellular vesicles from whole blood, plasma, urine, and saliva. The platform centers on proprietary antibody-surfaced microfluidic chips (sinusoidal for rare-cell capture, pillar for exosome subpopulations) combined with a catch-and-release chemistry using photoactivated (415 nm) or heat-activated enzymatic cleavable linkers, integrated onto Hamilton Microlab STAR/STARlet liquid handling robots via proprietary automation software.
The company sells three product lines: LiquidScan instruments installed at customer facilities, one-time-use consumable microfluidic chips and reagent kits (4- or 8-chip formats), and fee-for-service testing from its San Diego Core Lab. Pricing is quote-based and not publicly disclosed. Its primary customer segments are oncology researchers and clinicians (covering nine-plus cancer types including ovarian, colorectal, lung, pancreatic, and leukemia) and prenatal diagnostics researchers pursuing cell-based NIPT, with secondary reach into academic research institutions and immunotherapy developers. Named customers include the University of Kansas Medical Center, which has run LiquidScan systems continuously since 2022.
BioFluidica operates from three U.S. locations: a world headquarters in Cary, North Carolina; the Central Innovation Lab in Lawrence, Kansas; and a San Diego Core Facility. Leadership includes Co-Founder and CTO Dr. Steven A. Soper (Foundation Distinguished Professor at Kansas University, 310+ peer-reviewed publications, three-time NAI Fellow) and CEO Greg Studdard (former executive at GeneCare/Alere and Verinata Health, which was acquired by Illumina in 2013). The company raised over $6 million in a Series B2 round in February 2022 (with closings anticipated to $10M) and received MBArC/NIH RADx Tech grant funding to extend the platform toward handheld at-home disease testing. LiquidScan is currently labeled for Research Use Only; no FDA-cleared clinical diagnostic product has been disclosed.
BioFluidica firmographics
Firmographics- Name
- BioFluidica
- Legal name
- BioFluidica, Inc.
- Website
- https://biofluidica.com
- Company type
- Private
- Founded year
- 2013
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- BioFluidica is a privately held biotechnology company that has developed the LiquidScan microfluidics-based liquid biopsy platform, which isolates and enriches rare cells and exosomes from bodily fluids for oncology and prenatal diagnostics researchers.
- Ownership category
- akta.pro rank
BioFluidica industry classification
Industry- Product category
- Liquid Biopsy Diagnostics
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511), In-Vitro Diagnostic Substance Manufacturing (325413)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Surgical & Medical Instruments & Apparatus (3841), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes) (HLAAAMAH)
- akta.pro secondary industries
- Laboratory Automation, Sample Prep & Liquid Handling (IVD Lab Diagnostics) (HLAHAAAN), Biosensors & Lab-on-Chip (BioMEMS) (HDAHALAK)
Keywords
Where BioFluidica is headquartered
LocationHeadquarters
- HQ city
- Lawrence
- HQ country
- United States
- HQ region
- North America
Offices3 records
Markets served
BioFluidica business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Supply Chain, Operations, Marketing or Sales, Infrastructure
Revenue model
- LiquidScan Instrument Sales: Sale of LiquidScan processing module and reagent kits for installation in customer facilities (research institutions, clinical labs). The system is sold with associated microfluidic chips and reagents.
- Fee-for-Service Testing: BioFluidica offers services from their Core Labs on a fee-for-service basis, performing complete studies or pilot projects for customers who prefer not to operate their own systems.
- Reagent Kit Sales: Sale of reagent plates, microfluidic chips (4 or 8 per kit), sample tubes, and waste tubes. Reagent kits are one-time-use consumables that must be repurchased for each run.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| One time/ perpetual license | Multi-year contract | LiquidScan System - For installation in customer facilities |
| Other | Pay-as-you-go | Fee-for-Service Core Lab Testing |
| Unit Pricing | Pay-as-you-go | Reagent Kits (4 or 8 chips) |
Go-to-market motion1 record
Distribution channels2 records
Marketing channels5 records
BioFluidica product offering
Product offeringCore offering
BioFluidica develops and sells the LiquidScan® platform, a fully automated microfluidic system for isolating and enriching rare cells (circulating tumor cells, fetal trophoblasts) and exosomes from liquid biopsy samples including whole blood, plasma, urine, and saliva. The platform pairs proprietary antibody-surfaced microfluidic chips with a Hamilton Microlab STAR/STARlet liquid handling robot and uses catch-and-release cleavable-linker chemistry to release intact analytes compatible with downstream molecular analysis. The company also offers reagent kits, one-time-use microfluidic chips, and fee-for-service testing from its San Diego Core Lab.
Product overview
BioFluidica offers the LiquidScan® platform as its core product line, comprising an automated system (LiquidScan STAR(let)) that processes one-time-use microfluidic chips and reagent kits to isolate and enrich rare cells (CTCs, trophoblasts) and exosomes from liquid biopsy samples. The platform supports whole blood, plasma, urine, and saliva samples and produces output compatible with downstream molecular analysis methods including NGS, RNA-Seq, ddPCR, and qPCR. Additionally, BioFluidica is developing a Fetal Cell-Based DNA Test for prenatal diagnostics.
Differentiator
Problem solved
Functional benefit
Brands
- LiquidScan®: A fully-automated liquid biopsy platform for isolating and enriching rare cells (CTCs, trophoblasts) and exosomes from liquid biopsy samples using microfluidic chip technology.
Products and services
- LiquidScan Automated System Fully automated walk-away system for isolating and enriching rare cells and exosomes from liquid biopsy samples (whole blood, plasma, urine, saliva). Integrates with a Hamilton Microlab STAR or STARlet liquid handling robot and uses proprietary antibody-surfaced microfluidic chips with catch-and-release cleavable-linker chemistry. Used by oncology and prenatal researchers, academic core facilities, and pharmaceutical R&D teams.
- LiquidScan Microfluidic Chips One-time-use test-specific microfluidic devices with antibody-surfaced channels for capture, isolation, and enrichment of rare cells or exosomes. Available in sinusoidal (rare-cell) and pillar (exosome) chip formats. Chips can process 1-8 simultaneously. Sold as part of reagent kits to customers operating the LiquidScan system.
- LiquidScan Reagent Kits Reagent plate with contents ready to process 4 or 8 microfluidic chips, including antibody-surfaced chips, sample tubes, and waste/re-process sample tubes. One-time-use test-specific consumables that must be repurchased for each run.
- Fee-for-Service Core Lab Testing BioFluidica performs complete studies or pilot projects on a fee-for-service basis from its San Diego Core Facility for customers who prefer not to operate their own LiquidScan systems. Offers whole-blood, plasma, urine, and saliva sample processing for rare cell and exosome isolation.
Quantifiable outcome
- Captures rare cells at concentrations of 1-10 CTCs/ml in blood with high efficiency
- +3 more outcomes
Companies that use BioFluidica
Customer profileNamed customers2 records
Segments4 records
Ideal customer profiles4 records
BioFluidica technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
BioFluidica partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- University of Kansas Medical CentercoreBioFluidica equipped the liquid biopsy core facility at KUMC with LiquidScan systems to serve their clinical research needs. The systems have been continuously operating since 2022, testing applications and evolving user protocols. This partnership enables clinical validation and provides reference site for technology demonstration.
Scale indicators5 records
Recent moves5 records
Expansion highlights7 records
BioFluidica competitors and assessment
Company assessmentDirect peers
- Menarini Silicon Biosystems: Offers the CELLSEARCH CTC system and DEPArray for rare-cell isolation and downstream molecular analysis; directly competes with BioFluidica in circulating tumor cell capture and downstream characterization for liquid biopsy research and clinical use.
- Miltenyi Biotec: Provides microfluidic and magnetic-bead-based cell separation platforms (e.g., MACS, AutoMACS) widely used for rare-cell and exosome isolation in research and clinical settings; overlaps with BioFluidica's LiquidScan in target customers and application.
- RareCyte: Develops the AccuCyte and CytePicker platforms for CTC enumeration and retrieval from blood; competes head-to-head with LiquidScan in the rare-cell liquid biopsy research market.
- ANGLE plc: Markets the Parsortix microfluidic system for capturing CTCs from blood for downstream analysis; another direct competitor in antibody-independent microfluidic rare-cell capture, with overlap in oncology research applications.
- Bio-Techne: Provides exosome/EV isolation reagents (ExoQuick, Exo-spin) and analytical tools widely used in liquid biopsy research; competes with BioFluidica's pillar-chip exosome isolation in research-use workflows.
- Natera: Leader in cell-free DNA-based non-invasive prenatal testing (Panorama) and oncology liquid biopsy (Signatera); a direct competitor in the prenatal diagnostics market that BioFluidica's cbNIPT aims to enter with a cell-based (rather than cfDNA-based) approach.
Broad incumbents
- QIAGEN: Broad life-science and molecular diagnostics incumbent with liquid biopsy sample-prep kits (e.g., QIAamp circulating nucleic acid kits) and the QIAcuity digital PCR platform; competes as part of a much larger portfolio serving overlapping customers.
- Thermo Fisher Scientific: Sells laboratory automation (KingFisher, Ion Torrent) and a wide range of liquid biopsy reagents; relevant because BioFluidica's LiquidScan STAR(let) integrates with Hamilton robots and competes for the same lab budgets.
- Guardant Health: Dominant liquid biopsy company in oncology with Guardant360 and Reveal tests; competes in oncology liquid biopsy broadly, though its cfDNA-centric approach contrasts with BioFluidica's rare-cell and exosome focus.
Emerging players
- Standard BioTools (formerly Fluidigm): Provides microfluidics-based single-cell and biomarker analysis platforms with overlap in microfluidics expertise and liquid biopsy research customers, though its primary focus is broader multi-omics rather than CTC/exosome isolation.
Market position
Strengths5 records
Weaknesses4 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
BioFluidica social profiles
Digital presenceBioFluidica financial estimates
Financial estimateRevenue estimate
Valuation estimate
BioFluidica leadership team
Management profileNumber of profiles
Profiles6 records
BioFluidica funding detail
Funding detailFunding overview
Funding rounds7 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BioFluidica M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BioFluidica
What does BioFluidica do?
BioFluidica develops and sells the LiquidScan® platform, a fully automated microfluidic system for isolating and enriching rare cells (circulating tumor cells, fetal trophoblasts) and exosomes from liquid biopsy samples including whole blood, plasma, urine, and saliva. The platform pairs proprietary antibody-surfaced microfluidic chips with a Hamilton Microlab STAR/STARlet liquid handling robot and uses catch-and-release cleavable-linker chemistry to release intact analytes compatible with downstream molecular analysis. The company also offers reagent kits, one-time-use microfluidic chips, and fee-for-service testing from its San Diego Core Lab.
Is BioFluidica a public or private company?
BioFluidica is a private company. It is classified as venture growth investor backed and is currently operating.
When was BioFluidica founded?
BioFluidica was founded in 2013. It employs 11 to 50 people.
Where is BioFluidica based?
BioFluidica is headquartered in Lawrence, United States, in the North America region.
How does BioFluidica make money?
Three revenue lines are on record. LiquidScan Instrument Sales are the primary driver. The others are fee-for-Service Testing and reagent Kit Sales.
Who are BioFluidica's main competitors?
Direct peers on record are Menarini Silicon Biosystems, Miltenyi Biotec, RareCyte, ANGLE plc, Bio-Techne and Natera. Broad incumbents are QIAGEN, Thermo Fisher Scientific and Guardant Health. Standard BioTools (formerly Fluidigm) is listed as an emerging player.
Does BioFluidica have an API?
No public API is recorded for BioFluidica.
What industry is BioFluidica in?
BioFluidica's product category is Liquid Biopsy Diagnostics. Its primary akta.pro industry code is HLAAAMAH, Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes), with a secondary code of HLAHAAAN, Laboratory Automation, Sample Prep & Liquid Handling (IVD Lab Diagnostics). Its NAICS code is 541714 and its SIC code is 2835.